Why I Wouldn't Touch Novavax With a 10-Foot Pole

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either.

The Motley Fool • Dec 11, 2025

Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Dec 8, 2025

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Memo also reportedly mentions vaccines for flu and pneumonia.

Market Watch • Dec 1, 2025

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.

Investopedia • Dec 1, 2025

Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals

The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Barrons • Dec 1, 2025

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Nov 25, 2025

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Novavax, Inc. ( NVAX ) Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM EST Company Participants Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Welcome to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts cover semicap biotech in the U.S. It is my pleasure to have my next fireside chat with Novavax.

Seeking Alpha • Nov 19, 2025

Shah Capital pushes for Novavax sale, warns of proxy fight

Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is made in the next four months.

Reuters • Nov 12, 2025

Novavax to Participate in Jefferies London Healthcare Conference

GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Jefferies London Healthcare Conference: Fireside Chat Date: Wednesday, November 19, 2025 Time: 4:30 p.m.

PRNewsWire • Nov 12, 2025

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Nov 11, 2025